Tags

Type your tag names separated by a space and hit enter

Potential Anticancer Activity of Auranofin.
Chem Pharm Bull (Tokyo). 2019; 67(3):186-191.CP

Abstract

Gold compounds have a long history of use in medicine. Auranofin was developed more than 30 years ago as an oral therapy for rheumatoid arthritis. Now, however, auranofin is rarely used in clinical practice despite its efficacy for treating rheumatoid arthritis because more novel antirheumatic medications are available. Although its use in clinical practice has decreased, studies on auranofin have continued and it shows promise for the treatment of several different diseases, including cancer and bacterial and parasitic infections. Several potential novel applications of auranofin for treating human disease have been proposed. Auranofin inhibits the activity of thioredoxin reductase (TrxR), an enzyme of the thioredoxin (Trx) system that is important for maintaining the intracellular redox state. Particularly in cancers, TrxR inhibition leads to an increase in cellular oxidative stress and induces apoptosis. TrxR overexpression is associated with aggressive tumor progression and poor survival in patients with breast, ovarian, and lung cancers. The Trx system may represent an attractive target for the development of new cancer treatments. Therefore, the TrxR inhibitor auranofin may be a potent anticancer agent. This review summarizes the current understanding of auranofin for cancer therapy.

Authors+Show Affiliations

Institute of Microbial Chemistry (BIKAKEN), Numazu, Microbial Chemistry Research Foundation.Institute of Microbial Chemistry (BIKAKEN), Numazu, Microbial Chemistry Research Foundation.Institute of Microbial Chemistry (BIKAKEN), Numazu, Microbial Chemistry Research Foundation.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

30827998

Citation

Onodera, Takefumi, et al. "Potential Anticancer Activity of Auranofin." Chemical & Pharmaceutical Bulletin, vol. 67, no. 3, 2019, pp. 186-191.
Onodera T, Momose I, Kawada M. Potential Anticancer Activity of Auranofin. Chem Pharm Bull. 2019;67(3):186-191.
Onodera, T., Momose, I., & Kawada, M. (2019). Potential Anticancer Activity of Auranofin. Chemical & Pharmaceutical Bulletin, 67(3), 186-191. https://doi.org/10.1248/cpb.c18-00767
Onodera T, Momose I, Kawada M. Potential Anticancer Activity of Auranofin. Chem Pharm Bull. 2019;67(3):186-191. PubMed PMID: 30827998.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Potential Anticancer Activity of Auranofin. AU - Onodera,Takefumi, AU - Momose,Isao, AU - Kawada,Manabu, PY - 2019/3/5/entrez PY - 2019/3/5/pubmed PY - 2019/4/6/medline KW - anticancer drug KW - auranofin KW - drug repurposing KW - thioredoxin reductase KW - thioredoxin system SP - 186 EP - 191 JF - Chemical & pharmaceutical bulletin JO - Chem. Pharm. Bull. VL - 67 IS - 3 N2 - Gold compounds have a long history of use in medicine. Auranofin was developed more than 30 years ago as an oral therapy for rheumatoid arthritis. Now, however, auranofin is rarely used in clinical practice despite its efficacy for treating rheumatoid arthritis because more novel antirheumatic medications are available. Although its use in clinical practice has decreased, studies on auranofin have continued and it shows promise for the treatment of several different diseases, including cancer and bacterial and parasitic infections. Several potential novel applications of auranofin for treating human disease have been proposed. Auranofin inhibits the activity of thioredoxin reductase (TrxR), an enzyme of the thioredoxin (Trx) system that is important for maintaining the intracellular redox state. Particularly in cancers, TrxR inhibition leads to an increase in cellular oxidative stress and induces apoptosis. TrxR overexpression is associated with aggressive tumor progression and poor survival in patients with breast, ovarian, and lung cancers. The Trx system may represent an attractive target for the development of new cancer treatments. Therefore, the TrxR inhibitor auranofin may be a potent anticancer agent. This review summarizes the current understanding of auranofin for cancer therapy. SN - 1347-5223 UR - https://www.unboundmedicine.com/medline/citation/30827998/Potential_Anticancer_Activity_of_Auranofin_ L2 - https://dx.doi.org/10.1248/cpb.c18-00767 DB - PRIME DP - Unbound Medicine ER -